Companies › Bial R&D Investments
1 active drug program in 1 registered trial: 1 Phase 2; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BIA 28-6156 Glucocerebrosidase activator | GBA | Phase 2 | Parkinson's Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05819359 | BIA 28-6156 | Phase 2 | Parkinson's Disease | Neurology | Apr 2026 |
Lingyi Biotech Spur Therapeutics Prevail Therapeutics Azafaros
Aptinyx Neuron23 SHINKEI Therapeutics NeuroTherapia Clene Nanomedicine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.